Group 1 - The core viewpoint of the news is that the Kexin Innovation Drug ETF (589720) has seen a net inflow of over 770 million yuan for 10 consecutive days, indicating strong capital interest and potential price improvements for the product [1] - The raw material drug sector has experienced a price decline over the past 4-5 years, with most API product prices at historical lows, but there is an expectation of price recovery due to rising commodity and upstream chemical prices [1] - The commercialization of GLP-1 drugs is generating significant global demand for APIs and intermediates, while several small nucleic acid chronic disease drugs are entering a harvest phase, providing opportunities for raw material companies to expand into CDMO services [1] Group 2 - The Kexin Innovation Drug ETF (589720) tracks the Kexin Innovation Drug Index (950161), which has a daily price fluctuation limit of 20%, focusing on new drug development driven by technological innovation [1] - The index includes companies in the biopharmaceutical and chemical pharmaceutical sectors that have high R&D investment and innovation capabilities, reflecting the overall trend of innovation development in China's pharmaceutical industry [1] - The ETF's investment strategy emphasizes growth style, targeting companies with significant potential in the innovative drug sector [1]